绥美凯效果怎么样

It was approved for marketing in the United States in 2014. It has been approved in more than 100 countries, including my country, and has been recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. In addition to the original drug, the generic drug Suimeika produced by India's Emcure Pharmaceutical Company has also been welcomed by many patients.

Emcure Pharmaceuticals India is headquartered in Pune, India. Starting from a single manufacturing plant in Pune, it has rapidly grown into a series of world-class manufacturing plants and has become one of the top players in the domestic pharmaceutical industry in India. Its infrastructure, skills and resources are on par with the best pharmaceutical companies in the world. Covers production research of APIs, formulations and biotechnology.

The therapeutic effect of Suimeika produced by Emcure is basically the same as that of the original drug. Suimeike mainly contains three ingredients: abacavir, lamivudine and dolutegravir. Different ingredients have different effects.

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle).

Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted into the active metabolite carbavir triphosphate (CBV-TP), a deoxyguanosine-5'-triphosphate (dGTP) analogue, under the action of intracellular enzymes. CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate dGTP and inserting into viral DNA.

Lamivudine is a synthetic nucleoside analogue. Lamivudine is phosphorylated in cells to generate the active 5-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The main mode of action of 3T-CTP is to terminate DNA chain synthesis by inserting nucleotide analogs, thereby inhibiting RT activity.

One tablet is a complete treatment plan, and it is currently the only three-in-one compound drug containing dolutegravir (DTG). If patients need to purchase it, they can consult their medical companion or travel service for more information.

Recommended related hot articles: /newsDetail/87269.html